Stakeholder Engagement and Reporting

As a partner within the Canadian healthcare system, Roche believes that enhancing transparency will help us build trust within the communities in which we live and operate.

Transparency, for us, goes beyond the publication of financial statements and annual reports, to include open disclosure about our engagement with key stakeholders within the healthcare system, especially where this interaction helps fill a gap and/or barrier related to the delivery of care within our system.

We believe that engaging with health system stakeholders is essential to our understanding of their expectations, needs and concerns, as well as to identifying and filling gaps in the healthcare system.  By embedding their feedback and needs into our strategy, as well as our daily business, we are able to collectively address common issues and develop long-term solutions that prioritize patient outcomes.  These solutions may include novel medicines, diagnostics, as well as support programs and/or initiatives that drive education and access to care to help improve the overall health of Canadians.

Our interaction with stakeholders is governed not only by our own internal guidelines that outline a systematic process by which to engage stakeholders at a local and global level, but is also regulated by the Code of Ethical Practices of our industry association, Innovative Medicines Canada.

We, as a global organization, have taken numerous steps towards becoming more transparent about our interactions with stakeholders and making this information accessible, as we fundamentally believe that collaboration is the key to improving healthcare across the globe.  Collaboration between companies such as ours and healthcare providers, government, payers, patient organizations, as well as hospital institutions drives scientific advancements, enhances medical education, promotes health literacy and improves access to care across societies.

In support of our global commitment to transparency, Roche Canada is voluntarily publishing aggregated sums of payments made to Canadian healthcare providers (HCPs) and healthcare organizations (HCOs) in 2017 in the chart below.  This data will be updated on an annual basis and is being reported in accordance with the Voluntary Disclosure Framework that has been developed in partnership with and endorsed by Innovative Medicines Canada.


* Comments and Limitations on the Transfer of Value Data

  • Applicable taxes are excluded from the data.
  • Data may include certain related incidental expenses (such as, but not limited to, mileage reimbursement for travel).
  • Data is captured according to the payment date and not necessarily the date on which the activity occurred. Therefore, activities taking place in one year may not be reported until the subsequent year.
  • Payments made to healthcare organizations may include payments that were passed through to healthcare professionals as fee for service and, if so, will be captured in either category 1 or category 2, but the same payment will not be captured in both categories.
  • Total funding to healthcare organizations may also include payments to patient organizations, depending on how this information was entered into the reporting system at the time of the transaction.

Disclaimer:  Roche has made an effort to capture and present accurate and complete data in accordance with Innovative Medicines Canada’s Voluntary Framework for Payments to HCPs/HCOs.  However, the data has not been audited and may contain errors and omissions, and therefore is provided ‘as-is’, with no warranty or representation as to its accuracy or completeness.  Roche shall not be liable for damages resulting from the access, use or misuse of the data or from any errors or omissions in the data.

In addition to the above, Roche also invests significantly into medical research that is conducted in Canada.  In 2016 alone*,we invested $14.7 million CAD – roughly 13.5% of our global investment – to offer trials in 366 sites across the country, providing Canadians with the opportunity to access novel medicines for many debilitating and/or or life threatening diseases.

The Voluntary Disclosure Framework currently does not account for these investments or funding that is provided to patient organizations, which are reported separately as per the links below. 

Additional information about our activities and how we work with healthcare providers, government, payers, regulatory bodies, patient organizations, hospital institutions and other stakeholders is available here

*2017 numbers pending